养正消积胶囊联合培美曲塞及卡铂治疗表皮生长因子受体野生型或状态未知的老年转移性肺腺癌的临床研究  

Clinical Effect of Yangzhengxiaoji Capsule Combined with Pemetrexide and Carboplatin in the Treatment of EGFR Wild-type or Unknown Metastatic Lung Adenocarcinoma

作　　者：詹娟 傅建国[2] 宋敏[3] 张秋华[1] 吴炜新[1] 王馨[1] ZHAN Juan;FU Jian-guo;SONG Min(Department of Oncology,Zhongshan Hospital Affiliated to Xiamen University ,Xiamen,Fujian,361004,China)

机构地区：[1]厦门大学附属中山医院肿瘤内科,福建厦门361004 [2]厦门大学附属中山医院预防保健科,福建厦门361004 [3]厦门大学附属中山医院药学部,福建厦门361004

出　　处：《医学临床研究》2018年第11期2133-2135,共3页Journal of Clinical Research

摘　　要：【目的】探讨养正消积胶囊联合培美曲塞及卡铂治疗EGFR野生型或状态未知的老年转移性肺腺癌患者的临床疗效。【方法】选择本院收治的48例EGFR野生型或状态未知的老年转移性肺腺癌患者的临床资料,采取随机双盲对照的试验设计,将患者随机分为观察组和对照组,每组24例。观察组给予养正消积胶囊联合培美曲塞及卡铂化疗,对照组给予养正消积胶囊安慰剂联合培美曲塞及卡铂化疗。观察治疗期间两组患者不良反应,2个周期后评价近期临床疗效和生存质量。【结果】两组均无完全缓解(CR)病例。观察组客观有效率(ORR)为33.3%(8/24),疾病控制率(DCR)为83.3%(20/24),对照组ORR为25.0%(6/24),DCR为66.7%(16/24),两组疗效比较,差异均无统计学意义(均P>0.05)。两组主要的不良反应为骨髓抑制、消化道反应和疲乏,多为1~2级,两组均未发生4级或5级不良反应。观察组发生中性粒细胞减少、恶心、呕吐、肝功能损害、疲乏发生率显著小于对照组,差异具有统计学意义(P<0.05)。【结论】养正消积胶囊联合培美曲塞和卡铂治疗EGFR野生型或状态未知的老年转移性肺腺癌临床疗效较好,能明显减少或减轻化疗相关的不良反应,且能显著改善和稳定患者的症状,提高生存质量,值得临床推广。[objective]To investigate the clinical effect of Yangzhengxiaoji capsule combined with peme- trexide and carboplatin in the treatment of EGFR wild-type or unknown metastatic lung adenocarcinoma.[Methods] The clinical data of 48 patients with EGFR wild type or unknown status of metastatic lung adeno-carcinoma were selected. The patients were randomly divided into observation group and control group with 24 cases in each group.The observation group was treated with Yangzhengxiaoji capsule combined with pemetrex- ide and carboplatin chemotherapy, while the control group was treated with the placebo of Yangzhengxiaoji capsule combined with pemetrexide and carboplatin chemotherapy. Adverse reactions were observed in the two groups,and the clinical efficacy and quality of life (QOL) were evaluated after 2 cycles.【Results】There was no complete remission of (CR) in both groups.The objective effective rate (ORR) of the observation group was 33. 3%(8/24).The disease control rate (DCR) was 83.3% (8/24), the ORR of the control group was 25.5%(6/24),DCR= 66.7%(16/24),there was no significant difference between the two groups (mean P>0.05).The main adverse reactions in the two groups were bone marrow suppression, digestive tract reaction and fatigue,most of which were grade 1 or 2. No grade 4 or 5 adverse reactions occurred in both groups.The incidence of neutropenia,nausea, vomiting,liver function damage and fatigue in the observation group was significantly lower than that in the control group ( P<0.05).【Conclusion】 Yangzhengxiaoji capsule combined with pemetrexide and carboplatin in the treatment of EGFR wild-type or unknown senile metastatic lung ade-nocarcinoma has a good clinical effect, can significantly reduce or alleviate the adverse reactions associated with chemotherapy, and can significantly improve and stabilize the symptoms of patients,improve the quality of life.Thus,it is worth popularizing in clinic.

关 键 词：肺肿瘤/药物疗法 药物疗法 联合 

分 类 号：R734.2[医药卫生—肿瘤]